Exenatide: Further Studies Initiated

Exenatide: Further Studies Initiated
In 2012, The Cure Parkinson's Trust (CPT) initiated the International Linked Clinical Trials (iLCT) programme to focus on identifying and prioritising potentially disease-modifying therapies for Parkinson's. The first drug to be prioritised within the programme by the iLCT committee was a diabetes medication called exenatide. Since then, CPT has subsequently championed the repurposing of this drug and in 2017 the ... read more
Source: The Cure Parkinson’s TrustPublished on 2020-03-18